Base de dados : MEDLINE
Pesquisa : C04.557.450.795 [Categoria DeCS]
Referências encontradas : 21634 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2164 ir para página                         

  1 / 21634 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28954302
[Au] Autor:Fidler MM; Reulen RC; Winter DL; Allodji RS; Bagnasco F; Bárdi E; Bautz A; Bright CJ; Byrne J; Feijen EAM; Garwicz S; Grabow D; Gudmundsdottir T; Guha J; Haddy N; Jankovic M; Kaatsch P; Kaiser M; Kuonen R; Linge H; Maule M; Merletti F; Øfstaas H; Ronckers CM; Skinner R; Teepen J; Terenziani M; Vu-Bezin G; Wesenberg F; Wiebe T; Jakab Z; Haupt R; Lähteenmäki P; Zaletel LZ; Kuehni CE; Winther JF; de Vathaire F; Kremer LC; Hjorth L; Hawkins MM
[Ad] Endereço:Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France; Cancer and Radiation Team, U1018 INSERM, Villejuif, France; Epidemiology and Biosta
[Ti] Título:Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors. Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided. Results: Overall, survivors were 21.65 times (95% confidence interval = 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
[Mh] Termos MeSH primário: Neoplasias Ósseas/epidemiologia
Segunda Neoplasia Primária/epidemiologia
Sobreviventes/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Estudos de Coortes
Europa (Continente)/epidemiologia
Feminino
Seguimentos
Seres Humanos
Masculino
Osteossarcoma/epidemiologia
Retinoblastoma/epidemiologia
Sarcoma/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx165


  2 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27771610
[Au] Autor:Agulnik M; Costa RLB; Milhem M; Rademaker AW; Prunder BC; Daniels D; Rhodes BT; Humphreys C; Abbinanti S; Nye L; Cehic R; Polish A; Vintilescu C; McFarland T; Skubitz K; Robinson S; Okuno S; Van Tine BA
[Ad] Endereço:Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, USA.
[Ti] Título:A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
[So] Source:Ann Oncol;28(1):121-127, 2017 01 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: Soft tissue sarcomas (STSs) overexpress vascular endothelial growth factors (VEGF) and VEGF-receptors (VEGFR) activation have been associated with tumor aggressiveness. Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFRα/ß and cKIT. The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies. Patients and methods: A Simon two-stage phase II trial was performed using tivozanib given orally at 1.5 mg daily, 3 week on 1 week off on a 28 day cycle until disease progression or intolerable toxicity. Results: Fifty-eight patients were enrolled and treated with tivozanib. Leiomyosarcoma was the most common STS histological type in our cohort (47%) and 27 patients (46%) had received at least 3 lines of therapy prior to study entry. Up to 24 patients (41%) had prior VEGF targeted therapies. Partial response and stable disease were observed in 2 (3.6%) and 30 (54.5%) patients. The 16 week PFS rate was 36.4% [95% confidence interval (CI) 23.7-49.1] and a median PFS of 3.5 months (95% CI 1.8-3). Median OS observed was 12.2 months (95% CI 8.1-16.8). The most frequent all grade toxicities were fatigue (48.3%), hypertension (43.1%), nausea (31%) and diarrhea (27.6%). The most common grade three toxicity was hypertension (22.4%). Correlative studies demonstrate no correlation between the expression of VEGFR 1, 2 or 3, PDGFRα/ß or FGF, and activity of tivozanib. Conclusion: Tivozanib was well tolerated and showed antitumor activity with a promising median PFS and PFS rate at 4 months in a heavily pretreated population of metastatic STSs. Our results support further studies to assess the clinical efficacy of tivozanib in STS. Clinical Trial Number: NCT01782313.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Compostos de Fenilureia/uso terapêutico
Quinolinas/uso terapêutico
Sarcoma/tratamento farmacológico
Neoplasias de Tecidos Moles/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Intervalo Livre de Doença
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Imuno-Histoquímica
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Receptores de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
Sarcoma/mortalidade
Neoplasias de Tecidos Moles/mortalidade
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Phenylurea Compounds); 0 (Quinolines); 172030934T (tivozanib); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdw444


  3 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29315649
[Au] Autor:Fairweather M; Gonzalez RJ; Strauss D; Raut CP
[Ad] Endereço:Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
[Ti] Título:Current principles of surgery for retroperitoneal sarcomas.
[So] Source:J Surg Oncol;117(1):33-41, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Surgery for primary retroperitoneal sarcomas (RPS) often requires a technically challenging, en bloc multivisceral resection to optimize outcomes. Surgery may also be appropriate for patients with localized recurrent RPS. Anatomic considerations and tumor biology driven by histologic subtype may guide the extent of resection in patients with RPS. This review provides an overview of the current surgical principles for primary and recurrent RPS.
[Mh] Termos MeSH primário: Neoplasias Retroperitoneais/cirurgia
Sarcoma/cirurgia
[Mh] Termos MeSH secundário: Seres Humanos
Neoplasias Retroperitoneais/patologia
Sarcoma/patologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24919


  4 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29314041
[Au] Autor:MacNeill AJ; Fiore M
[Ad] Endereço:Division of Surgical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
[Ti] Título:Surgical morbidity in retroperitoneal sarcoma resection.
[So] Source:J Surg Oncol;117(1):56-61, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Resection of retroperitoneal sarcoma (RPS) typically involves multivisceral resection. The morbidity of RPS resection has decreased over time despite widespread adoption of radical resection. Certain patterns of resection are associated with higher complication rates and elderly patients are at increased risk of morbidity. Administration of preoperative radiotherapy does not increase morbidity, but intraoperative and brachytherapy techniques are associated with heightened toxicities. Long-term functional outcomes and quality of life scores after RPS resection are acceptable.
[Mh] Termos MeSH primário: Qualidade de Vida
Neoplasias Retroperitoneais/epidemiologia
Neoplasias Retroperitoneais/cirurgia
Sarcoma/epidemiologia
Sarcoma/cirurgia
[Mh] Termos MeSH secundário: Seres Humanos
Morbidade
Neoplasias Retroperitoneais/patologia
Sarcoma/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24902


  5 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29284068
[Au] Autor:Zerhouni S; Van Coevorden F; Swallow CJ
[Ad] Endereço:Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
[Ti] Título:The role and outcomes of palliative surgery for retroperitoneal sarcoma.
[So] Source:J Surg Oncol;117(1):105-110, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Categories of noncurative surgery for retroperitoneal sarcoma include: i) grossly incomplete resection (R2) of primary or locally recurrent tumor; ii) resection in the setting of distant metastatic disease; and iii) true palliative-intent symptom-directed surgery. The value of R2 resection is debatable, since most series do not report initial operative intent. Debulking surgery provides symptom relief in the majority of patients, but relief is generally not durable. Quality of life is poorly studied.
[Mh] Termos MeSH primário: Cuidados Paliativos
Qualidade de Vida
Neoplasias Retroperitoneais/cirurgia
Sarcoma/cirurgia
[Mh] Termos MeSH secundário: Seres Humanos
Neoplasias Retroperitoneais/patologia
Sarcoma/patologia
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171229
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24934


  6 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266220
[Au] Autor:Callegaro D; Miceli R; Gladdy RA
[Ad] Endereço:Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
[Ti] Título:Prognostic models for RPS patients-Attempting to predict patient outcomes.
[So] Source:J Surg Oncol;117(1):69-78, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Retroperitoneal sarcoma (RPS) patients can have variable of outcomes after surgery. The chance to recur locally or at distant sites varies according to tumor grade, histologic subtype, and other patient- and tumor-related characteristics. The relative contribution of each prognostic variable on the oncological outcome of RPS patients can be weighted by combining them in prognostic tools such as nomograms. With this review, we critically appraise the available nomograms for RPS patients highlighting pros and cons.
[Mh] Termos MeSH primário: Modelos Estatísticos
Neoplasias Retroperitoneais/cirurgia
Sarcoma/cirurgia
[Mh] Termos MeSH secundário: Seres Humanos
Prognóstico
Neoplasias Retroperitoneais/patologia
Sarcoma/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24903


  7 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29230829
[Au] Autor:Renne SL; Iwenofu OH
[Ad] Endereço:Sarcoma and Pediatric Pathology Unit, Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istutito Nazionale dei Tumori, Milano, Italy.
[Ti] Título:Pathology of retroperitoneal sarcomas: A brief review.
[So] Source:J Surg Oncol;117(1):12-24, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sarcomas represent a highly heterogeneous group of tumors as reflected in the significant overlap between their histologic phenotypes between the different types, posing diagnostic challenges for the pathologist. Definitive tumor classification is increasingly important because of prognostication and emergence of targeted therapies for some of the sarcoma types. In this review, we highlight pertinent pathologic and molecular aspects of sarcomas common in the retroperitoneum, relevant to the surgical oncologist.
[Mh] Termos MeSH primário: Neoplasias Retroperitoneais/classificação
Neoplasias Retroperitoneais/patologia
Sarcoma/classificação
Sarcoma/patologia
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24928


  8 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29194633
[Au] Autor:Constantinidou A; Jones RL
[Ad] Endereço:Medical School University of Cyprus & The BoC Oncology Centre, Nicosia, Cyprus.
[Ti] Título:Systemic therapy in retroperitoneal sarcoma management.
[So] Source:J Surg Oncol;117(1):87-92, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There is paucity of randomized controlled data on the role of systemic therapy in retroperitoneal sarcomas. The type of systemic therapy used is guided by the histological subtype. The majority of retroperitoneal sarcomas comprising liposarcomas and leiomyosarcomas are by and large chemotherapy insensitive. There is an urgent need for more efficacious systemic therapies in the management of early and advanced stage retroperitoneal sarcomas.
[Mh] Termos MeSH primário: Neoplasias Retroperitoneais/terapia
Sarcoma/terapia
[Mh] Termos MeSH secundário: Terapia Combinada
Gerenciamento Clínico
Seres Humanos
Neoplasias Retroperitoneais/patologia
Sarcoma/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24933


  9 / 21634 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29194630
[Au] Autor:Tzanis D; Bouhadiba T; Gaignard E; Bonvalot S
[Ad] Endereço:Department of Surgery, Sarcoma Unit, Institute Curie, PSL University, Paris, France.
[Ti] Título:Major vascular resections in retroperitoneal sarcoma.
[So] Source:J Surg Oncol;117(1):42-47, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Retroperitoneal sarcomas (RPS) frequently involve major vessels, which either originate from them or secondarily encase or invade them. In this field, major vascular resections result in increased morbidity. However, survival does not seem to be affected by the need for vascular resection or by this higher morbidity. This paper aims to provide descriptions of the surgical strategy and outcomes for retroperitoneal sarcomas involving major vessels.
[Mh] Termos MeSH primário: Neoplasias Retroperitoneais/cirurgia
Sarcoma/cirurgia
Neoplasias Vasculares/cirurgia
[Mh] Termos MeSH secundário: Seres Humanos
Neoplasias Retroperitoneais/patologia
Sarcoma/patologia
Resultado do Tratamento
Neoplasias Vasculares/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24920


  10 / 21634 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29193081
[Au] Autor:Zaidi MY; Canter R; Cardona K
[Ad] Endereço:Division of Surgical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
[Ti] Título:Post-operative surveillance in retroperitoneal soft tissue sarcoma: The importance of tumor histology in guiding strategy.
[So] Source:J Surg Oncol;117(1):99-104, 2018 Jan.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Crafting effective surveillance strategies for retroperitoneal soft tissue sarcomas is difficult given the scarcity of literature on this rare disease. In this article, we will summarize the most recent literature on natural history and recurrence patterns of RPS compiled from multi-institutional collaborative studies and centers with extended follow-up data, and based on this evidence, propose principles for histology-based post-operative surveillance protocols.
[Mh] Termos MeSH primário: Técnicas Histológicas/métodos
Vigilância da População
Complicações Pós-Operatórias/diagnóstico
Neoplasias Retroperitoneais/patologia
Sarcoma/patologia
[Mh] Termos MeSH secundário: Terapia Combinada
Seres Humanos
Complicações Pós-Operatórias/epidemiologia
Neoplasias Retroperitoneais/terapia
Sarcoma/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24927



página 1 de 2164 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde